ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Zhang, L. [1 ]
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Ma, R. [10 ]
Bi, M. [11 ]
Ren, X. [12 ]
Zhou, J. [13 ]
Li, B. [14 ]
Xu, W. [15 ]
Ji, Y. [15 ]
Peng, B. [15 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Shandong Prov Canc Hosp, Jinan, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Tumor Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
[6] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[10] Liaoning Canc Hosp, Shenyang, Peoples R China
[11] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[15] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期
关键词：
anti-PD-1; antibody; chemotherapy; nsqNSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ID:1329
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [1] Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
    Zhang, Li
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Stefaniak, Victoria
    Lin, Yong
    Wang, Shuyan
    Zhang, Wen
    Sun, Luyao
    Yang, Yunpeng
    [J]. LUNG CANCER, 2022, 171 : 56 - 60
  • [2] Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
    Yang, Yunpeng
    Sun, Jiya
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Ma, Rui
    Bi, Minghong
    Ren, Xiubao
    Zhou, Jianying
    Li, Baolan
    Song, Yong
    Feng, Jifeng
    Li, Juan
    He, Zhiyong
    Zhou, Rui
    Li, Weimin
    Lu, You
    Zhou, Hui
    Wang, Shuyan
    Sun, Luyao
    Puig, Oscar
    Mancao, Christoph
    Peng, Bo
    Fang, Wenfeng
    Xu, Wei
    Zhang, Li
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2109 - 2120
  • [3] Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11)
    Yang, Yunpeng
    Zhou, Hui
    Zhang, Li
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (12) : E191 - E192
  • [4] Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
    Yang, Y.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Stefaniak, V.
    Lin, Y.
    Wang, S.
    Zhang, W.
    Sun, L.
    Zhang, Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S28 - S28
  • [5] Outcomes of sintilimab plus pemetrexed and platinum (SPP) according to stage of disease in patients (pts) with locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase 3 ORIENT-11 study.
    Yang, Yunpeng
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Stefaniak, Victoria Jennifer
    Ferry, David Raymond
    Zhao, Yumin
    Wang, Shuyan
    Wang, Yan
    Sun, Luyao
    Zhang, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
    Fang, J.
    Zhao, Y.
    Han, B.
    Chen, G.
    Yang, Z.
    Bi, M.
    Zhang, L.
    Molife, C.
    Zhao, Y.
    Zhang, L.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1415 - S1415
  • [7] Sintilimab plus platinum-based chemotherapy for non-squamous NSCLC
    Venkatesan, Priya
    [J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [8] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] PEMETREXED PLUS PLATINE IN FIRST LINE FOR TREATMENT OF ADVANCED AND METASTATIC NON-SQUAMOUS CELL LUNG CANCER
    Mehenni, Nawel
    Bensaou, Malika Gamaz
    Bouzid, Kamel
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1164 - S1164
  • [10] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345